STAT

Font of despair: In the fierce competition for science funding, even a typeface glitch can be fatal

A doctor's "fatal error" was not medical but typographical: His funding request for a PTSD project on veterans didn't get past the VA's ruler-wielding enforcers of fonts and type size.

When he first saw the email, just after finishing rounds in the surgical intensive care unit, Dr. Joseph Schlesinger began to panic. A government staffer was writing to inform him that he’d made “a fatal error.”

Standing at the nurses’ pod, surrounded by patients in various states of post-surgical woe, he wondered what he should do next. Life-sustaining machines whirred around him, residents discussed prognoses — but he heard nothing. “It was like I was in a vacuum,” said Schlesinger, an assistant professor of anesthesiology and critical care medicine at Vanderbilt University and a staff physician at the Veterans Affairs medical center in Nashville. None of the cases in front of him needed his immediate attention, and so he left to address the crisis in his inbox.

His “fatal error” was not medical

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

Related Books & Audiobooks